EP2, EP4, and DP1 prostanoid receptors

Class

First-in-class small-molecule EP2/EP4/DP1 triple antagonist

Pathway

Blocks COX/prostaglandin (PGE2/PGD2)-driven immunosuppression in the tumor microenvironment, restoring anti-tumor immune function

Prostaglandins are small lipid signaling molecules built from arachidonic acid through the cyclooxygenase (COX) enzyme pathway. Two of them, PGE2 and PGD2, are produced in large amounts by many solid tumors and act on cell-surface receptors called EP2, EP4, and DP1. Although these are three separate receptors responding to two different prostaglandins, they all raise levels of the same internal messenger, cyclic AMP, inside immune cells. Elevated cyclic AMP in T cells, natural killer cells, and myeloid cells dampens their tumor-killing activity and favors recruitment of immunosuppressive cell types, helping tumors evade an immune response even when tumor-reactive immune cells are present nearby. Because more than one receptor and more than one prostaglandin can produce this same suppressive effect, blocking only one node leaves redundant routes open. A small molecule designed to antagonize EP2, EP4, and DP1 together aims to close off this suppressive signaling more completely than a single-receptor agent could. This differs from broadly inhibiting the COX enzymes themselves, which reduces all downstream prostaglandins and related lipids and carries well-documented effects on the stomach lining, kidneys, and blood vessels. The mechanism is relevant broadly across cancers where a prostaglandin-rich, immunosuppressive tumor microenvironment limits the effectiveness of immune-based therapies.